Anaphylaxis Market

Market Overview:

The 7 major anaphylaxis markets reached a value of USD 3.7 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 6.9 Billion by 2035, exhibiting a growth rate (CAGR) of 5.8% during 2025-2035.

The anaphylaxis market has been comprehensively analyzed in IMARC's new report titled "Anaphylaxis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Anaphylaxis refers to a severe and potentially life-threatening allergic reaction that develops rapidly after exposure to an allergen. In this condition, the body's immune system releases a flood of chemicals, such as histamine, which can cause a range of indications throughout the body. These symptoms may include itching, redness, and swelling on the skin, difficulty breathing, wheezing, coughing, tightness in the chest, a rapid or weak pulse, low blood pressure, dizziness or fainting, nausea, vomiting, abdominal pain, diarrhea, etc. In some cases, individuals suffering from the ailment may also experience anxiety, a sense of impending doom, and confusion. The diagnosis of anaphylaxis is typically based on a combination of clinical features, a physical examination, and the patient's medical history. Various blood workups are also utilized to measure certain substances in the blood, such as tryptase and histamine levels, that are associated with allergic reactions. The healthcare provider may further perform skin prick or intradermal tests, in which small amounts of suspected allergens are applied to the skin to identify specific toxins causing the underlying symptoms.

The rising prevalence of insect stings, including those from bees, wasps, fire ants, etc., that trigger the release of various chemicals, like histamine and numerous other mediators, into the bloodstream is primarily driving the anaphylaxis market. In addition to this, the increasing incidence of mast cell disorders, in which the immune system mistakenly attacks the body's tissues, leading to inflammation, is creating a positive outlook for the market. Moreover, the widespread adoption of epinephrine therapy, since it works quickly to constrict blood vessels, relax smooth muscles, and decrease the severity of allergic reactions, is further bolstering the market growth. Apart from this, the inflating application of corticosteroids, such as prednisone and methylprednisolone, on account of their several advantages, like reducing inflammation, preventing the risk of late-phase symptoms, enhancing the quality of life, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced autoinjector devices that are designed with features, including visual cues and audio instructions, making them easier for non-medical bystanders to use in an emergency, is expected to drive the anaphylaxis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the anaphylaxis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for anaphylaxis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anaphylaxis market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the anaphylaxis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the anaphylaxis market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current anaphylaxis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the anaphylaxis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the anaphylaxis across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the anaphylaxis across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of anaphylaxis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of anaphylaxis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of anaphylaxis by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with anaphylaxis across the seven major markets?
• What is the size of the anaphylaxis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of anaphylaxis?
• What will be the growth rate of patients across the seven major markets?
   

Anaphylaxis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for anaphylaxis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the anaphylaxis market?
• What are the key regulatory events related to the anaphylaxis market?
• What is the structure of clinical trial landscape by status related to the anaphylaxis market?
• What is the structure of clinical trial landscape by phase related to the anaphylaxis market?
• What is the structure of clinical trial landscape by route of administration related to the anaphylaxis market?